Anti-LY75-CD302 monoclonal antibody

Pre-made anti-LY75-CD302 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to LY75-CD302/LY75-CD302 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP1130-Ab-1/ GM-Tg-hg-IP1130-Ab-2Anti-Human LY75-CD302 monoclonal antibodyHuman
GM-Tg-rg-IP1130-Ab-1/ GM-Tg-rg-IP1130-Ab-2Anti-Rat LY75-CD302 monoclonal antibodyRat
GM-Tg-mg-IP1130-Ab-1/ GM-Tg-mg-IP1130-Ab-2Anti-Mouse LY75-CD302 monoclonal antibodyMouse
GM-Tg-cynog-IP1130-Ab-1/ GM-Tg-cynog-IP1130-Ab-2Anti-Cynomolgus/ Rhesus macaque LY75-CD302 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP1130-Ab-1/ GM-Tg-felg-IP1130-Ab-2Anti-Feline LY75-CD302 monoclonal antibodyFeline
GM-Tg-cang-IP1130-Ab-1/ GM-Tg-cang-IP1130-Ab-2Anti-Canine LY75-CD302 monoclonal antibodyCanine
GM-Tg-bovg-IP1130-Ab-1/ GM-Tg-bovg-IP1130-Ab-2Anti-Bovine LY75-CD302 monoclonal antibodyBovine
GM-Tg-equg-IP1130-Ab-1/ GM-Tg-equg-IP1130-Ab-2Anti-Equine LY75-CD302 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP1130-Ab-1/ GM-Tg-hg-IP1130-Ab-2; GM-Tg-rg-IP1130-Ab-1/ GM-Tg-rg-IP1130-Ab-2;
GM-Tg-mg-IP1130-Ab-1/ GM-Tg-mg-IP1130-Ab-2; GM-Tg-cynog-IP1130-Ab-1/ GM-Tg-cynog-IP1130-Ab-2;
GM-Tg-felg-IP1130-Ab-1/ GM-Tg-felg-IP1130-Ab-2; GM-Tg-cang-IP1130-Ab-1/ GM-Tg-cang-IP1130-Ab-2;
GM-Tg-bovg-IP1130-Ab-1/ GM-Tg-bovg-IP1130-Ab-2; GM-Tg-equg-IP1130-Ab-1/ GM-Tg-equg-IP1130-Ab-2
Products NameAnti-LY75-CD302 monoclonal antibody
Formatmab
Target NameLY75-CD302
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-LY75-CD302 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP1130-Ag-1Recombinant multi-species LY75-CD302/ CD205/ CLEC13B protein


    Target information

    Target IDGM-IP1130
    Target NameLY75-CD302
    Gene ID100526664,100126287,100101125,100060284
    Gene Symbol and SynonymsCD205,CD302,CLEC13B,DEC-205,gp200-MR6,Ly-75,LY5,LY75,LY75-CD302,LYT75
    Uniprot AccessionN/A
    Uniprot Entry Name
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000248672
    Target ClassificationN/A

    The target: LY75-CD302, gene name: LY75-CD302, also named as CD205, CLEC13B, DEC-205, LY75, Ly-75, gp200-MR6. This locus represents naturally occurring read-through transcription between the neighboring lymphocyte antigen 75 (LY75) and CD302 molecule (CD302) genes. Alternative splicing results in multiple transcript variants encoding fusion products that share sequence identity with each individual gene product. [provided by RefSeq, Nov 2010].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.